Thanks for posting when it came out today. To a
Post# of 30027
Posted On: 03/08/2016 8:07:03 PM
Thanks for posting when it came out today.
Not sure this was widely known. Lonza didn't pocket the $3M. Obviously a $8B company wants this to success as do many others.
Add to that the DoD is picking up most the expense of the trial.
Quote:
To acquire the rights to ESS, Amarantus paid Lonza Group a fee of $3.15 million in cash. In return, Lonza has committed to spending a good portion of the payment on preparing the initiation of the Phase II clinical study.
Not sure this was widely known. Lonza didn't pocket the $3M. Obviously a $8B company wants this to success as do many others.
Add to that the DoD is picking up most the expense of the trial.
(3)
(2)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼